IN2014DN02060A - - Google Patents
Info
- Publication number
- IN2014DN02060A IN2014DN02060A IN2060DEN2014A IN2014DN02060A IN 2014DN02060 A IN2014DN02060 A IN 2014DN02060A IN 2060DEN2014 A IN2060DEN2014 A IN 2060DEN2014A IN 2014DN02060 A IN2014DN02060 A IN 2014DN02060A
- Authority
- IN
- India
- Prior art keywords
- patient
- benzimidazol
- methylpiperazin
- quinolin
- tautomer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a method of treating a cancer in patient in need thereof by administering 4 amino 5 fluoro 3 [6 (4 methylpiperazin 1 yl) 1H benzimidazol 2 yl] 1H quinolin 2 one or a tautomer thereof or a salt of any one of them wherein the patient is a moderate hepatic impaired patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535142P | 2011-09-15 | 2011-09-15 | |
| PCT/US2012/054046 WO2013039764A1 (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN02060A true IN2014DN02060A (en) | 2015-05-15 |
Family
ID=46846036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2060DEN2014 IN2014DN02060A (en) | 2011-09-15 | 2012-09-07 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140221389A1 (en) |
| EP (1) | EP2755655A1 (en) |
| JP (1) | JP2014526506A (en) |
| KR (1) | KR20140062485A (en) |
| CN (1) | CN103826634A (en) |
| AU (1) | AU2012308993A1 (en) |
| BR (1) | BR112014005653A2 (en) |
| CA (1) | CA2848210A1 (en) |
| IN (1) | IN2014DN02060A (en) |
| MX (1) | MX2014003182A (en) |
| RU (1) | RU2014114827A (en) |
| WO (1) | WO2013039764A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| EP3093014A1 (en) * | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1650203E (en) | 2000-09-11 | 2008-05-13 | Novartis Vaccines & Diagnostic | Process of preparation of benzimidazol-2-yl quinolinone derivatives |
| BR0313743A (en) | 2002-08-23 | 2005-07-05 | Chiron Corp | Benzimidazole quinolinones and uses of these |
| AU2003290699B2 (en) * | 2002-11-13 | 2009-08-27 | Novartis Vaccines And Diagnostics, Inc. | Methods of treating cancer and related methods |
| CN100377709C (en) * | 2002-11-13 | 2008-04-02 | 希龙公司 | Methods of treating cancer and related methods |
| DE602004022540D1 (en) * | 2003-05-27 | 2009-09-24 | Robert P Haegerkvist | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES |
| CA2609353C (en) | 2005-05-23 | 2015-04-28 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
| PE20091628A1 (en) | 2008-03-19 | 2009-11-19 | Novartis Ag | CRYSTALLINE FORMS AND TWO SOLVATED FORMS OF LACTIC ACID SALTS OF 4-AMINO-5-FLUORO-3- [5- (4-METHYLPIPERAZIN-1-IL) -1H-BENZIMIDAZOL-2-IL] QUINOLIN-2 (1H) - ONA |
| EA201200617A1 (en) * | 2009-11-23 | 2012-11-30 | Серулин Фарма Инк. | POLYMERS ON THE BASIS OF CYCLODEXTRINE FOR DELIVERY OF MEDICINES |
-
2012
- 2012-09-07 CA CA2848210A patent/CA2848210A1/en not_active Abandoned
- 2012-09-07 US US14/342,612 patent/US20140221389A1/en not_active Abandoned
- 2012-09-07 CN CN201280044613.4A patent/CN103826634A/en active Pending
- 2012-09-07 EP EP12758976.0A patent/EP2755655A1/en not_active Withdrawn
- 2012-09-07 AU AU2012308993A patent/AU2012308993A1/en not_active Abandoned
- 2012-09-07 JP JP2014530703A patent/JP2014526506A/en active Pending
- 2012-09-07 MX MX2014003182A patent/MX2014003182A/en not_active Application Discontinuation
- 2012-09-07 IN IN2060DEN2014 patent/IN2014DN02060A/en unknown
- 2012-09-07 KR KR1020147006625A patent/KR20140062485A/en not_active Application Discontinuation
- 2012-09-07 BR BR112014005653A patent/BR112014005653A2/en not_active IP Right Cessation
- 2012-09-07 WO PCT/US2012/054046 patent/WO2013039764A1/en active Application Filing
- 2012-09-07 RU RU2014114827/15A patent/RU2014114827A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014114827A (en) | 2015-10-20 |
| JP2014526506A (en) | 2014-10-06 |
| WO2013039764A1 (en) | 2013-03-21 |
| CN103826634A (en) | 2014-05-28 |
| BR112014005653A2 (en) | 2017-03-28 |
| US20140221389A1 (en) | 2014-08-07 |
| EP2755655A1 (en) | 2014-07-23 |
| KR20140062485A (en) | 2014-05-23 |
| CA2848210A1 (en) | 2013-03-21 |
| MX2014003182A (en) | 2014-09-22 |
| AU2012308993A1 (en) | 2014-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA515360469B1 (en) | Heterocyclic compounds for inhibiting glutaminase and their methods of use | |
| PH12015501965A1 (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| UA118759C2 (en) | 3,4-dihydroisoquinolin-2(1h)-yl compounds | |
| MX362550B (en) | Heterocyclic inhibitors of glutaminase. | |
| UA115231C2 (en) | Imidazohyrrolidinone compounds | |
| IN2014MN00988A (en) | ||
| IN2014MN01640A (en) | ||
| WO2012173682A3 (en) | Compounds and methods for the treatment of isocitrate dehydrognase related diseases | |
| NZ709153A (en) | Pyrimidinone derivatives having human neutrophil elastase inhibitory activity | |
| MX2015002669A (en) | Methods of administering pirfenidone therapy. | |
| IN2014DN10670A (en) | ||
| PH12015501586A1 (en) | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors | |
| IN2015DN01151A (en) | ||
| EA201391171A1 (en) | RIFAXIMINE FORMS AND THEIR APPLICATION | |
| IN2015MN00002A (en) | ||
| MX2018002885A (en) | Salts of a pim kinase inhibitor. | |
| WO2014160281A3 (en) | Method of enhancing delivery of therapeutic compounds to the eye | |
| EA032271B9 (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| NZ700356A (en) | Pyrazole compounds as sglt1 inhibitors | |
| MX357763B (en) | Treatment for pancreatic cancer. | |
| UA109942C2 (en) | Normal;heading 1;heading 2;heading 3;2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | |
| PH12014502065A1 (en) | Vesicular formulations | |
| IN2014DN03010A (en) | ||
| IN2014DN02060A (en) | ||
| EA033124B1 (en) | Use of a fused bicyclic 2,4-diaminopyrimidine derivative for treating alk- or fak-mediated disease or disorder in a subject |